Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk

2020202 citationsJournal Articlehybrid Open Access

Authors

Mansoor Husain · Toronto General Hospital

Stephen C. Bain · Swansea University

Ole Kleist Jeppesen · Novo Nordisk (Denmark)

Ildiko Lingvay · Southwestern Medical Center

Rasmus Sørrig · Novo Nordisk (Denmark)

Marianne Bach Treppendahl · Novo Nordisk (Denmark)

Tina Vilsbøll ·

Abstract

In SUSTAIN and PIONEER combined, glucagon-like peptide-1 analogue semaglutide showed consistent effects on MACE versus comparators across varying CV risk. No effect of semaglutide on MACE was observed in subjects with prior HF.

Topics & Keywords

Diabetes Treatment and Management Metabolism, Diabetes, and Cancer Diet and metabolism studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Diabetes Obesity and Metabolism

Volume 22, Issue 3, pp. 442-451

DOI: 10.1111/dom.13955

Field-Weighted Citation Impact: 15.77